LENZ Therapeutics, Inc.(LENZ)

Biotechnology · Solana Beach, CA

$3.79+0.20 (+5.62%)

Delayed quote: Oct 6, 2026, 11:49 AM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T15:52:00.090Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:52:00.090Z.

Quote observation: 2026-10-06T15:49:44.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 118,889,591
TTM operating cash flow · period ending 2026-06-30: -113,908,000

FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

LENZ Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

LENZ Competitors' Price/OCF Ratio

LENZ

LENZ Therapeutics, Inc.

Current

Market Cap

$118.89M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRBU

Caribou Biosciences, Inc.

vs LENZ

Market Cap

$117.53M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMDX

Insight Molecular Diagnostics Inc.

vs LENZ

Market Cap

$116.57M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GNLX

Genelux Corporation

vs LENZ

Market Cap

$116.81M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COYA

Coya Therapeutics, Inc.

vs LENZ

Market Cap

$116.34M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HURA

TuHURA Biosciences, Inc.

vs LENZ

Market Cap

$121.00M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FHTX

Foghorn Therapeutics Inc.

vs LENZ

Market Cap

$116.25M

Price/OCF Ratio

N/A

TTM Avg

1.65

3Y Avg

1.65

5Y Avg

1.65

CBUS

Cibus, Inc.

vs LENZ

Market Cap

$122.89M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUCD

Lucid Diagnostics Inc.

vs LENZ

Market Cap

$115.00M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENGN

enGene Holdings Inc.

vs LENZ

Market Cap

$122.93M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
LENZ Therapeutics, Inc. (LENZ)	$118.89M	N/A	N/A	N/A	N/A
Caribou Biosciences, Inc. (CRBU)vs ›	$117.53M	N/A	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$116.57M	N/A	N/A	N/A	N/A
Genelux Corporation (GNLX)vs ›	$116.81M	N/A	N/A	N/A	N/A
Coya Therapeutics, Inc. (COYA)vs ›	$116.34M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$121.00M	N/A	N/A	N/A	N/A
Foghorn Therapeutics Inc. (FHTX)vs ›	$116.25M	N/A	1.65	1.65	1.65
Cibus, Inc. (CBUS)vs ›	$122.89M	N/A	N/A	N/A	N/A
Lucid Diagnostics Inc. (LUCD)vs ›	$115.00M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$122.93M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

LENZ Price/OCF Ratio Metrics

LENZ Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics